Search results for "reati"

showing 10 items of 3038 documents

Estudio de la respuesta psicofisiológica a estresores de laboratorio en deportistas

1999

:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAPsychology PhysiologicalHealth Sciences Recreation
researchProduct

Actitudes y percepción de riesgo ante el consumo de alcohol en adolescentes: efectos diferenciales respecto a jovenes consumidores de alcohol y cocaí…

2006

La experimentación con alcohol y otras sustancias psicoactivas por parte del colectivo juvenil se vincula a un estilo de ocio recreativo compartido con el grupo de iguales con búsqueda de la sobreestimulación y como mecanismo de reafirmación de la identidad grupal. Desde una aproximación psicosocial como la aportada se propone un análisis de la esfera actitudinal bajo una triple dimensionalidad: factores cognitivos (creencias, expectativas, percepciones, etc.), afectivos (identificación con los usuarios, agrado o desagrado, etc.) y comportamentales (inclinación para la aceptación del hábito). También se explora la percepción de riesgos y la conciencia de daño físico y/o psicosocial derivado…

:PSICOLOGÍA::Psicofarmacología [UNESCO]:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAAdolescentes alcohol cocaína consumo recreativo actitudes percepciones de riesgo representaciones sociales.UNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what …

2019

Albuminuria; Atrasentan; Canagliflozin Albuminuria; Atrasentan; Canagliflozina Albuminúria; Atrasentan; Canagliflozina In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. Both trials demonstrated significant nephroprot…

:compuestos heterocíclicos::compuestos heterocíclicos de 1 anillo::dioxoles::benzodioxoles::atrasentán [COMPUESTOS QUÍMICOS Y DROGAS]030232 urology & nephrologysodium-glucose cotransporter-2 (SGLT2) inhibitor:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Diabetic nephropathychemistry.chemical_compound0302 clinical medicineChronic kidney diseaseClinical endpointNefropaties diabètiques - Tractament:Other subheadings::/therapeutic use [Other subheadings]canagliflozin:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]CanagliflozinSglt2 Inhibitors:enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES]Sodium-glucose cotransporter-2 (SGLT2) inhibitorNephrologyendothelinmedicine.drugmedicine.medical_specialty:hidratos de carbono::glicósidos::glucósidos::canagliflozina [COMPUESTOS QUÍMICOS Y DROGAS]UrologyRenal functionalbuminuriaEndothelinNephropathy:Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES]03 medical and health sciencesmedicineAlbuminuriaPirrolidina - Ús terapèutic:Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Dioxoles::Benzodioxoles::Atrasentan [CHEMICALS AND DRUGS]CanagliflozinDiabetic kidney diseaseTransplantationCreatinine:Carbohydrates::Glycosides::Glucosides::Canagliflozin [CHEMICALS AND DRUGS]atrasentan:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryAtrasentanGlucòsids - Ús terapèuticmedicine.diseasediabetic kidney diseasechemistryAtrasentanbusinesschronic kidney diseaseKidney disease
researchProduct

Two cases of monomicrobial intraabdominal abscesses due to KPC - 3 Klebsiella pneumoniaeST258 clone

2011

Abstract Background Knowledge of the etiology of pyogenic liver and pancreatic abscesses is an important factor in determining the success of combined surgical and antibiotic treatment. Literature shows geographical variations in the prevalence and distribution of causative organisms, and the spread of Klebsiella pneumoniae carbapenemase-producing bacteria is an emerging cause of abdominal infections. Case presentation We herein describe two cases of intra-abdominal abscesses due to monomicrobial infection by Klebsiella pneumoniae Sequence Type 258 producing K. pneumoniae carbapenemase 3 (KPC-Kp). In case 1, a 50-year-old HIV-negative Italian woman with chronic pancreatitis showed infection…

<it>Klebsiellae pneumoniae</it>medicine.medical_specialtyAbdominal AbscessSettore MED/17 - Malattie Infettivecarbapenemasesmedicine.drug_classKlebsiella pneumoniaeAntibioticsMinocyclineCase ReportDrug resistanceTigecyclineTigecyclinebeta-LactamasesBacterial ProteinsDrug Resistance Multiple BacterialPancreatitis ChronicInternal medicinemedicineHumanslcsh:RC799-869Klebsiellae pneumoniaeSettore MED/12 - GastroenterologiabiologyColistinbusiness.industryAbdominal InfectionLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsSurgeryPancreatic NeoplasmsSettore MED/18 - Chirurgia GeneraleKlebsiella pneumoniaeColistinPancreatitislcsh:Diseases of the digestive system. Gastroenterologymonomicrobial abscess Klebsiellae pneumoniae carbapenemasesFemalebusinessmonomicrobial abscessmedicine.drugLiver abscessBMC Gastroenterology
researchProduct

Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Met…

2016

Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Methods and Findings Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. T…

ACE inhibitorsMyocardial InfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE inhibitor therapyBiochemistryRenin-Angiotensin SystemAnginachemistry.chemical_compoundEndocrinologyMathematical and Statistical Techniques0302 clinical medicineReninMedicine and Health SciencesSecondary Prevention030212 general & internal medicineMyocardial infarctionDiureticsStrokePharmaceuticsRDrugsEnzyme inhibitorsCardiovascular therapyGeneral Medicine3. Good healthHospitalizationStrokeNephrologyCardiovascular DiseasesPhysical SciencesCardiologyMedicineDrug therapyStatistics (Mathematics)Research Articlemedicine.drugAdultmedicine.medical_specialtyEndocrine DisordersCardiologyResearch and Analysis MethodsAngina PectorisDiabetes ComplicationsAngiotensin Receptor Antagonists03 medical and health sciencesDiabetes mellitusInternal medicineRenal DiseasesDiabetes MellitusmedicineHumansStatistical MethodsRenal Insufficiency ChronicPharmacologyHeart FailureCreatinineBiology and life sciencesbusiness.industryOdds ratiomedicine.diseasechemistryMetabolic DisordersHeart failuresistema cardiovascularACE inhibitorEnzymologyKidney Failure ChronicbusinessMathematicsMeta-AnalysisPLOS Medicine
researchProduct

PROOXIDATIVE MECHANISM OF ACTION OF PERACETIC ACID IN CELLULAR MODEL OF ACUTE PANCREATITIS

ACUTE PANCREATITIS; OXIDATIVE STRESS ETHANOLOXIDATIVE STRESS ETHANOLACUTE PANCREATITIS
researchProduct

The relationship between organizational interdependency and additionality obtained from innovation ecosystem participation

2019

Abstract Despite the increased interest in innovation ecosystems, few studies have assessed the extent to which the proclaimed benefits from participating in such ecosystems also occur, and under which circumstances they do occur. Uniting the literature on organizational interdependence and social exchange theory, we assess the behavioral and output additionality obtained by innovation ecosystem participants. In doing so, we build upon a sample of 473 innovative Finnish companies, of which 312 participated in an innovation ecosystem. We find a significantly positive relationship between organizational interdependence and output additionality, and find that this relationship is mediated by b…

ALLIANCE FORMATIONPublic AdministrationGeography Planning and DevelopmentSample (statistics)Management Monitoring Policy and LawSOCIAL-EXCHANGE THEORYCOLLABORATIONBusiness and Economicsorganizational interdependenceVALUE CREATIONAdditionalityadditionalityBOARD COMPOSITIONSUPPORTDEVELOPMENT SUBSIDIESEcosystemSTRATEGYValue creationPublic economicsRESEARCH-AND-DEVELOPMENTPOLICYinnovation ecosystemsocial exchange theoryComputingMilieux_GENERALSocial exchange theoryEarth and Environmental SciencesPositive relationshipBusiness
researchProduct

Metformin influences drug sensitivity in pancreatic cancer cells

2018

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction o…

AMPK0301 basic medicineCancer Researchendocrine system diseases03 medical and health sciencesPancreatic cancerGeneticsMedicineAnimalsHumansDoxorubicinDrug InteractionsRapamycinSignal transduction inhibitormTORC1Molecular BiologyCisplatinSirolimusAnimalbusiness.industryPancreatic NeoplasmCancermedicine.diseaseGemcitabineMetforminMetforminPancreatic Neoplasms030104 developmental biologyDrug InteractionDocetaxelDiabetes Mellitus Type 2SirolimusCancer researchMolecular MedicinebusinessHumanmedicine.drugCarcinoma Pancreatic DuctalSignal Transduction
researchProduct

EP1224 Predictors and clinical outcome of pancreatic fistula in patients receiving splenectomy for advanced or recurrent ovarian cancer: a large mult…

2019

Introduction/Background The aim of the surgical treatment of advanced ovarian cancer is to completely remove all macroscopic disease.To achieve optimal cytoreduction, the use of extensive upper abdominal surgery has become widely accepted.Although the disease doesn’t usually invade the splenic parenchyma, the capsule may commonly be infiltrated. These metastases may be difficult to be dissected from the pancreatic tail and a partial pancreatic resection en bloc with spleen may be required. The objective of this study is to evaluate predictors and clinical outcome of pancreatic fistula in patients receiving splenectomy for advanced or recurrent ovarian cancer. Methodology Data of women recei…

Abdominal painChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentSplenectomyDiseasemedicine.diseaseSurgeryPancreatic fistulaRecurrent Ovarian CancerPancreatectomyMedicinemedicine.symptombusinessOvarian cancerePoster Talks: Ovarian + Endometria
researchProduct

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

2020

Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis. Therefore, there is a significant unmet medical need for effective triglyceride-lowering drugs for patients with FCS. Case report: We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. Lomitapide treatment resulted in a reduction of fasting TG levels from 2897 mg/dL (32.71 mmol/L) to an average of 954 mg/dL (10.77 mmol/L) on the 30 mg lomitapide equating to a 67% reduction from baseline. After 26 months of lomita…

Abdominal painPediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRecurrent pancreatitisInternal medicineFatty liverHumansMedicineProspective Studiesmedicine.diagnostic_testbusiness.industryFatty liverHypertriglyceridemiaFCSFamilial Chylomicronemiamedicine.diseaseLomitapideLomitapideAcute pancreatitisPancreatitischemistry030220 oncology & carcinogenesisLiver biopsyAcute DiseaseAcute pancreatitisPancreatitisBenzimidazolesHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessFamilial chylomicronaemia syndromeAtherosclerosis
researchProduct